Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
about
Advances in the treatment of rheumatoid arthritis.Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.Rheumatoid arthritis: identifying and characterising polymorphisms using rat modelsRituximab for Rheumatoid Arthritis.Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory StudyBiologics registers in RA: methodological aspects, current role and future applications.A rheumatoid factor paradox: inhibition of rituximab effector function.Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaborationBiomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis.Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patientsThe Effects of Blast Exposure on Protein Deimination in the BrainAnti-citrullinated protein antibodies cause arthritis by cross-reactivity to joint cartilage.Memory B cell subsets and plasmablasts are lower in early than in long-standing rheumatoid arthritis.CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients.Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only studyRituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response.Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm.Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry.The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countriesCross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patientsEvolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonistsSuppressed diversity of survivin splicing in active rheumatoid arthritis.HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritisRheumatoid arthritis treatment with TNF inhibitors and alternative procedures in case of its failure - results of the Polish survey in the context of EULAR recommendationsA combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study.Rituximab for the treatment of rheumatoid arthritis: an update.RA in 2011: Advances in diagnosis, treatment and definition of remission.Review on the influence of protocol design on clinical outcomes in rheumatoid arthritis treated with rituximab.Comparison of characteristics of international and national databases for rheumatoid arthritis: a systematic literature review.Efficacy and safety of rituximab in rheumatic diseases.Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting.Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry.Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.Functional and Structural Characterization of a Novel HLA-DRB1*04:01-Restricted α-Enolase T Cell Epitope in Rheumatoid ArthritisMonitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment.
P2860
Q27691822-754D34C1-4068-4547-8C91-29852AB2CFD7Q27692641-A44BC879-B5C3-48C7-91B7-60B968D53412Q28073099-05EC08CE-5B5B-45B5-A86D-BDB2506D1A1CQ28080246-472867E9-0B29-46A7-9720-3D0E7F338C51Q28551216-C6DD68D1-77F4-43A1-B6FC-22A0A8C60E01Q30234303-F687675F-450C-4F7C-8FF5-47AEDDF466B7Q30418884-D32727A3-1F1F-4C4F-B84E-08F9B98A3608Q31046441-0364ABA9-AC12-4A9E-8E66-592C176E0E32Q31078960-7495134D-CE73-4C80-91BA-3210E955BFD6Q33765608-04A75B06-BB16-406A-8AF5-8A996B296532Q33775472-979C1247-83C0-4E77-A9A7-A8F9AEC6BF03Q33877817-060CED47-290B-441B-B89D-2EE8B7FABD78Q34208191-61447461-A14D-41B7-93EB-F47706784E99Q34895182-857337EB-3B6B-47B1-84CB-7A5EDF6DFB92Q35544546-316DE02A-7502-49E2-BB98-F3B067A0C258Q35605438-74D9CB1E-5E37-4EE0-B5B2-A0218DB1814AQ35654669-12EA1BE7-8F6E-4CF1-A7F7-1D00CD194320Q35751550-15CE1B40-8AC3-4CD9-A230-D3A14F729CBFQ35809549-B7D28EA4-5856-4FD7-935C-25B0EED72B9AQ35835741-50039931-A3DE-4006-9980-E3C892141E25Q36071720-3648FD9E-B7D7-4AE0-812A-F4BB9A274AF6Q36183803-445DA568-99D0-4633-A83E-A584B480E361Q36214720-1BF9EA3F-3871-475C-AC00-4EC0E09070DCQ36245889-A7483FE4-4561-4C22-80F8-13D99E9A01C1Q36406242-8611F93F-DFC8-47E0-83DF-CF365D73EA9BQ36433351-78C4B447-68B3-42E5-8B65-F5ED6D15E757Q36810546-92BCA00B-FBEF-4C50-A428-CD5422BE77B7Q36842389-7AFBF6D4-C041-43B6-A0B1-7DE2A0F71C5DQ37203531-421D923D-63E8-4502-BD15-71F44AFA2542Q37444678-C4E2AFB0-7EB9-4C33-A50A-DC03F55EE8B7Q37974496-52C2945D-144F-462E-87BC-5D77A51012CFQ38085279-73C0BA07-8055-4256-B0DB-94632D7F1C12Q38217664-DB743F50-455D-4E52-9258-20130A2D5C2AQ38353577-554B3655-28CA-451E-BC48-44A916104229Q38857820-61AACB41-324C-4570-80E5-C54BE16D3B6FQ39029106-12DF2404-ADC4-4187-9E9B-78516F0147BCQ40047193-A3C896A4-E3F8-49F4-9246-21C5E61BD518Q40055726-498EAC80-0A10-4399-B33D-2CEB88961D8FQ40432151-078F1846-60BE-408B-AF49-2FD90B374438Q40624064-84849089-D099-4AEB-B2E7-C87E998FFA58
P2860
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Highest clinical effectiveness ...... a from 10 European registries.
@ast
Highest clinical effectiveness ...... a from 10 European registries.
@en
type
label
Highest clinical effectiveness ...... a from 10 European registries.
@ast
Highest clinical effectiveness ...... a from 10 European registries.
@en
prefLabel
Highest clinical effectiveness ...... a from 10 European registries.
@ast
Highest clinical effectiveness ...... a from 10 European registries.
@en
P2093
P50
P356
P1476
Highest clinical effectiveness ...... a from 10 European registries.
@en
P2093
Dan C Nordström
Elisabeth Lie
Evgeny Nasonov
Galina Lukina
Juan Gomez-Reino
Matija Tomsic
Piet L C M van Riel
Ulrik Tarp
P304
P356
10.1136/ARD.2010.148759
P407
P50
P577
2011-05-12T00:00:00Z